Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394351 | 0.87 | KMT2A (0.51) | MAPTNPSR1KMT2AHSD17B10DHFR | |
| SCHEMBL7880012 | 0.82 | MAPT (0.52) | MAPTNPSR1KMT2AHSD17B10DHFR | |
| SCHEMBL7886614 | 0.76 | SCD (0.56) | MAPTNPSR1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL3242066 | 0.74 | DRD2 (0.48) | MAPTNPSR1KMT2ADHFRPIK3CA | |
| SCHEMBL3242089 | 0.74 | TSHR (0.53) | MAPTNPSR1KMT2AHSD17B10DHFR | |
| SCHEMBL2494773 | 0.74 | DHFR (0.59) | MAPTNPSR1DHFRMTORTSHR | |
| SCHEMBL7884723 | 0.74 | ALDH1A1 (0.52) | MAPTNPSR1KMT2AHSD17B10MEN1 | |
| SCHEMBL3243110 | 0.73 | MGLL (0.49) | MAPTNPSR1KMT2ADHFRPIK3CA | |
| SCHEMBL4997745 | 0.70 | PHGDH (0.50) | MAPTNPSR1KMT2AHSD17B10DHFR | |
| SCHEMBL7883356 | 0.70 | MAPT (0.47) | MAPTNPSR1KMT2AHSD17B10DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993452-B1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-05 | — | — | EP | claimed |
| US-6833369-B2 | Treatment of ocular neovascular diseases, neovascular glaucoma, diabetic retinopathy, | JANSSEN PHARMACEUTICA, NV (BE) | 2004-12-21 | — | — | US | claimed |
| US-20040009987-A9 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4,-THIADIAZOLYL DERIVATIVES | STOKBROEKX RAYMOND ANTOINE (BE) | 2004-01-15 | — | — | US | claimed |
| US-20030181460-A1 | Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-25 | — | — | US | claimed |
| US-20020061890-A1 | Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives | STOKBROEKX RAYMOND ANTOINE (BE) | 2002-05-23 | — | — | US | claimed |
| EP-0993452-A1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-19 | — | — | EP | claimed |
| WO-1998058919-A1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-30 | — | — | WO | claimed |
| EP-0993452-B1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-05 | — | — | EP | disclosed |
| US-7208503-B2 | Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-24 | — | — | US | disclosed |
| US-6833369-B2 | Treatment of ocular neovascular diseases, neovascular glaucoma, diabetic retinopathy, | JANSSEN PHARMACEUTICA, NV (BE) | 2004-12-21 | — | — | US | disclosed |
| US-20040009987-A9 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4,-THIADIAZOLYL DERIVATIVES | STOKBROEKX RAYMOND ANTOINE (BE) | 2004-01-15 | — | — | US | disclosed |
| US-20030181460-A1 | Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-25 | — | — | US | disclosed |
| US-20020061890-A1 | Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives | STOKBROEKX RAYMOND ANTOINE (BE) | 2002-05-23 | — | — | US | disclosed |
| EP-0993452-A1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058919-A1 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009987-A9 | ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4,-THIADIAZOLYL DERIVATIVES | PTGS1, PTGER1, PTGIS | MAPT 4880/4885NPSR1 1126/4885KMT2A 3747/4885 |
| US-20030181460-A1 | Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives | PTGS1, PTGER1, ALOX15B | MAPT 4874/4885NPSR1 1406/4885KMT2A 3560/4885 |
| US-20020061890-A1 | Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives | PTGS1, PTGER1, PTGIS | MAPT 4880/4885NPSR1 1126/4885KMT2A 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.